Daniel S Heller

US Patent:

20220276171, Sep 1, 2022

Filed:

Oct 8, 2021

Appl. No.:

17/497325

Inventors:

- New York NY, US
Daniel A. HELLER - New York NY, US
Daniel ROXBURY - New York NY, US

International Classification:

G01N 21/64
B82Y 15/00
B82Y 30/00
B82Y 5/00
A61B 5/145
A61B 5/1455

Abstract:

A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SW-CNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.

US Patent:

20210353607, Nov 18, 2021

Filed:

Oct 4, 2019

Appl. No.:

17/282657

Inventors:

- New York NY, US
Daniel Alan Heller - New York NY, US
Carles Monterrubio Martinez - Boston MA, US
Amaia Arruabarrena Aristorena - New York NY, US
Peter T. Meinke - Scotch Plains NJ, US
Michael Andrew Foley - New York NY, US
Yasutomi Asano - Chigasaki-city, JP
Kazuyoshi Aso - Yokohama, JP
Hiroki Takahagi - Yokohama, JP
Yosef Shamay - Zichron Yaakov, IL
Jose Manuel Baselga Torres - New York NY, US
Yusuke Sasaki - Yokohamashi, JP
Mayako Michino - New York NY, US

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY
Tri-lnstitutional Therapeutics Discovery Institute, Inc. - New York NY

International Classification:

A61K 31/4439
A61K 9/16
A61K 49/00
C07D 417/14
A61K 31/427
A61P 35/00

Abstract:

The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3Kα inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3Kα) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.

US Patent:

20210262017, Aug 26, 2021

Filed:

Aug 20, 2020

Appl. No.:

16/998762

Inventors:

- New York NY, US
Daniel HELLER - New York NY, US
Prakrit JENA - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

C12Q 1/6834

Abstract:

Described herein are novel devices and methods for the optical detection of oligonucleotide binding events for diagnostic, point-of-care, drug screening, and theranostic applications, for example, a robust and customizable system to detect specific DNA and RNA oligonucleotides using a carbon nanotube optical signal.

US Patent:

20190383744, Dec 19, 2019

Filed:

Aug 22, 2019

Appl. No.:

16/548491

Inventors:

- New York NY, US
Daniel A. HELLER - New York NY, US
Daniel ROXBURY - New York NY, US

International Classification:

G01N 21/64
A61B 5/1455
A61B 5/145
B82Y 15/00
B82Y 30/00
B82Y 5/00

Abstract:

A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SWCNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.

US Patent:

20190142960, May 16, 2019

Filed:

Jan 7, 2019

Appl. No.:

16/241954

Inventors:

- New York NY, US
Daniel A. HELLER - New York NY, US
Yosef SHAMAY - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

A61K 47/61
A61K 41/00
A61K 9/06
A61K 31/337
A61K 31/704
A61K 47/69
A61K 47/64
A61K 47/58
A61K 51/06
A61K 9/51
A61K 9/00
A61K 31/737
A61K 31/517
A61K 31/475
A61K 31/4184
A61K 47/60
A61K 31/4412
A61K 49/00

Abstract:

Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.

US Patent:

20180011072, Jan 11, 2018

Filed:

Jun 6, 2017

Appl. No.:

15/615802

Inventors:

- Cambridge MA, US
Daniel A. Heller - Rye Brook NY, US
George W. Pratt - Melrose MA, US
Jingqing Zhang - Cambridge MA, US

Assignee:

MASSACHUSETTS INSTITUTE OF TECHNOLOGY - CAMBRIDGE MA

International Classification:

G01N 33/22
B82Y 30/00
G01N 21/64

Abstract:

Systems and methods related to optical nanosensors comprising photoluminescent nanostructures are generally described.

US Patent:

20170199126, Jul 13, 2017

Filed:

May 28, 2015

Appl. No.:

15/313580

Inventors:

- New York NY, US
Daniel A. Heller - New York NY, US
Daniel Roxbury - New York NY, US

International Classification:

G01N 21/64
A61B 5/1455
A61B 5/145

Abstract:

A method of detecting a condition in a subject comprises the steps of contacting cells of the subject with single-walled carbon nanotubes (SWCNTs), monitoring photoluminescence emitted by SWCNTs internalized into the cells and generating an SWCNT emission profile, comparing the SWCNT emission profile to a control emission profile for the SWCNTs to produce a result, and determining a likelihood of having the condition in the subject based on the result from the comparing step. Also disclosed is a method for screening agents capable of changing endocytic environment using SWCNTs.

US Patent:

20160178597, Jun 23, 2016

Filed:

Jun 10, 2013

Appl. No.:

13/914236

Inventors:

- Cambridge MA, US
Daniel A. Heller - Rye Brook NY, US
George W. Pratt - Melrose MA, US
Jingqing Zhang - Cambridge MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA

International Classification:

G01N 33/22
G01N 21/64

Abstract:

Systems and methods related to optical nanosensors comprising photoluminescent nanostructures are generally described.